Ono Pharmaceutical has entered a collaboration with BioFocus, the service division of Galapagos NV, for the discovery of novel drugs in the field of CNS disorders. BioFocus will use its drug discovery platform to deliver leads and clinical candidates to Ono. Financial details were not disclosed.
"We are delighted to have this new agreement, which is the first drug discovery program with this, a most valued, client," said Dr. Chris Newton, senior vice president of Galapagos Services and managing director of BioFocus. "This project plays to BioFocus historic strengths and the expanding breadth and depth of this partnership is testament to a tried and trusted relationship."
Kazuhito Kawabata, Ph.D., Member of the board of directors, executive officer and executive director, Discovery and Research of Ono, said, "We have the highest regard for the BioFocus' comprehensive drug discovery platform. This collaboration will strengthen Ono's drug discovery capability in the field of CNS disorders with significant unmet medical needs and we are expecting that innovative drugs will be created through this collaboration."